Drug Profile

Tiragolumab - Genentech

Alternative Names: anti-TIGIT - Roche; MTIG-7192A; RG-6058; RG6058-10; RG6058-11; RO 7092284

Latest Information Update: 29 Apr 2026

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Genentech
Developer Chugai Pharmaceutical; Genentech; National Cancer Institute (USA); Roche; Washington University School of Medicine
Class Antineoplastics; Immunotherapies; Monoclonal antibodies
Mechanism of Action Antibody-dependent cell cytotoxicity; T lymphocyte stimulants; TIGIT protein inhibitors

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

Discontinued B-cell lymphoma; Cervical cancer; Gastric cancer; Liver cancer; Malignant melanoma; Multiple myeloma; Non-small cell lung cancer; Oesophageal cancer; Rectal cancer; Renal cell carcinoma; Small cell lung cancer; Solid tumours; Squamous cell cancer; Triple negative breast cancer; Urogenital cancer

15 Apr 2026 Roche terminates a phase Ib/II Morpheus C trial for Gastric cancer or Gastroesophageal cancer (Combination therapy, Late-stage disease, Metastatic disease, First-line therapy) in China (IV, Infusion) as the sponsor decided not to continue development of certain treatment combinations (NCT05251948)
11 Mar 2026 Roche terminates a phase II trial in Non-small cell lung cancer (Combination therapy, First-line therapy, Late-stage disease, Neoadjuvant therapy) in USA, Switzerland, Australia, Italy, Netherlands, Poland, South Korea, Spain (IV) as data became available from phase III trials (NCT04832854)
22 Jan 2026 Genentech in collaboration with University of Pittsburgh terminates a phase II trial in Non-small cell Lung cancer (Combination therapy) in USA (IV) due to decision of agent provider (NCT05746481)

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com